The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Ketamine and the next generation of antidepressants with a rapid onset of action
Open accessAbstract
Existing treatments for major depressive disorder (MDD) usually take weeks to months to achieve their antidepressant effects, and a significant number of patients do not have adequate improvement even after months of treatment. In addition, increased risk of suicide attempts is a major public health concern during the first month of standard antidepressant therapy. Thus, improved therapeutics that can exert their antidepressant effects within hours or a few days of their administration are urgently needed, as is a better understanding of the presumed mechanisms associated with these rapid antidepressant effects. In this context, the N-methyl-D-aspartate (NMDA) antagonist ketamine has consistently shown antidepressant effects within a few hours of its administration. This makes it a valuable research tool to identify biomarkers of response in order to develop the next generation of fast-acting antidepressants. In this review, we describe clinical, electrophysiological, biochemical, and imaging correlates as relevant targets in the study of the antidepressant response associated with ketamine, and their implications for the development of novel, fast-acting antidepressants. We also review evidence that alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) to NMDA throughput may represent a convergent mechanism for the rapid antidepressant actions of ketamine. Overall, understanding the molecular basis of this work will likely lead to the ultimate development of improved therapeutics for MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 2×
“Furthermore, despite the relatively large number of antidepressants available (Rush et al., 2006; Trivedi et al., 2006), our limited understanding of both the pathophysiology of MDD and the mechanisms of action involved in the therapeutic effects of antidepressants have been significant impediments to developing impro…”
BackgroundDeep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059 · cited 2×
“A consistent association between increased subgenual cingulate (Cg25) activity and acute sadness has also been noted using positron emission tomography (PET); in this study, application of chronic deep brain stimulation (DBS) close to the subgenual cingulate region (Brodmann’s area 25) reduced the elevated activity in…”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 3×
“Furthermore, despite the relatively large number of antidepressants available (Rush et al., 2006; Trivedi et al., 2006), our limited understanding of both the pathophysiology of MDD and the mechanisms of action involved in the therapeutic effects of antidepressants have been significant impediments to developing impro…”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationAMPA Receptor Trafficking and Synaptic Plasticity
Malinow, R., & Malenka, R. C. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142758 · Cited by 2,588
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 1×
“In this context, stress and neuroplasticity have also been shown to play a role in MDD, and these are also critically regulated by the glutamatergic system (Pittenger & Duman, 2008).”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citation
Cited by
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
“Normalization of these neuroplastic deficits might contribute not only to the relatively sustained antidepressant effects of ketamin”
BackgroundInflammation, glutamate, and glia: a trio of trouble in mood disorders
Haroon, E., Miller, A. H., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.199 · Cited by 584
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
The kynurenine pathway and the brain: Challenges, controversies and promises
Schwarcz, R., & Stone, T. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.003 · Cited by 461
Zhou, W., Wang, N., Yang, C., Li, X.-M., Zhou, Z.-Q., & Yang, J.-J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.10.005 · Cited by 390
“Unfortunately, the delayed onset time and the low remission rate of these conventional antidepressants are still major challenges [16,10].”
BackgroundR (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304
Kynurenine pathway in depression: a systematic review and meta-analysis
Ogyu, K., Kubo, K., Noda, Y., Iwata, Y., Tsugawa, S., Omura, Y., Wada, M., Tarumi, R., Plitman, E., Moriguchi, S., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.023 · Cited by 301
Beurel, E., Song, L., & Jope, R. S. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.47 · Cited by 288
Scheidegger, M., Walter, M., Lehmann, M., Metzger, C., Grimm, S., Boeker, H., Boesiger, P., Henning, A., & Seifritz, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044799 · Cited by 282
“Based on the increasing evidence of glutamate-modulating agents having strong and rapid antidepressant properties [1,2], the NMDA receptor antagonist ketamine has been firmly established as a research tool for the investigation of the neurobiology of the glutamatergic system in major depressive disorder (MDD) and nove…”
BackgroundZarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Self-citationNeuroplasticity Underlying the Comorbidity of Pain and Depression
Doan, L., Manders, T., & Wang, J. (2015) · Neural Plasticity · doi:10.1155/2015/504691 · Cited by 282
Burgdorf, J., Panksepp, J., & Moskal, J. R. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.11.011 · Cited by 258
Aleksandrova, L. R., Phillips, A. G., & Wang, Y. T. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160175 · Cited by 228
Cell atrophy and loss in depression: reversal by antidepressant treatment
Banasr, M., Dwyer, J. M., & Duman, R. S. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.002 · Cited by 201
Ferreira Mello, B. S., Monte, A. S., McIntyre, R. S., Soczynska, J. K., Custódio, C. S., Cordeiro, R. C., Chaves, J. H., Mendes Vasconcelos, S. M., Nobre Júnior, H. V., Florenço de Sousa, F. C., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.06.008 · Cited by 195
Guardiola‐Lemaitre, B., De Bodinat, C., Delagrange, P., Millan, M. J., Munoz, C., & Mocaër, E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12720 · Cited by 182
Yang, C., Hu, Y.-M., Zhou, Z.-Q., Zhang, G.-F., & Yang, J.-J. (2013) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.724118 · Cited by 173
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
Self-citationKetamine for the treatment of addiction: evidence and potential mechanisms
Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.017 · Cited by 163
“However, one study in human patients with depression failed to show an increase in BDNF plasma levels 4 h after ketamine infusion (Machado-Vieira et al., 2009) and further”
Fischell, J., Van Dyke, A. M., Kvarta, M. D., LeGates, T. A., & Thompson, S. M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.112 · Cited by 122
Mao, J., Li, T., Fan, D., Zhou, H., Feng, J., Liu, L., Zhang, C., & Wang, X. (2020) · BMC Psychiatry · doi:10.1186/s12888-019-2374-2 · Cited by 120
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.07.007 · Cited by 114
Jett, J. D., Bulin, S. E., Hatherall, L. C., McCartney, C. M., & Morilak, D. A. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.01.017 · Cited by 92
“Moreover, acute low-dose administration of the N-methyl-Daspartate (NMDA) receptor antagonist, ketamine, has been shown to induce rapid antidepressant effects in treatment-resistant patients (Carlson et al., 2006; Zarate et al., 2006; Machado-Vieira et al., 2009).”
BackgroundBrand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Yamanaka, H., Yokoyama, C., Mizuma, H., Kurai, S., Finnema, S. J., Halldin, C., Doi, H., & Onoe, H. (2014) · Translational Psychiatry · doi:10.1038/tp.2013.112 · Cited by 84
Ketamine administration reduces amygdalo‐hippocampal reactivity to emotional stimulation
Scheidegger, M., Henning, A., Walter, M., Lehmann, M., Kraehenmann, R., Boeker, H., Seifritz, E., & Grimm, S. (2016) · Human Brain Mapping · doi:10.1002/hbm.23148 · Cited by 79
“The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has been shown to exhibit antidepressant properties and is currently used as a probe for the investigation of novel antidepressant drug targets [Aan Het Rot et al., 2012; Machado-Vieira et al., 2009] since it shows a much faster onset of action and is partic…”
BackgroundJett, J. D., Boley, A. M., Girotti, M., Shah, A., Lodge, D. J., & Morilak, D. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3957-3 · Cited by 75
Gärtner, M., Aust, S., Bajbouj, M., Fan, Y., Wingenfeld, K., Otte, C., Heuser-Collier, I., Böker, H., Hättenschwiler, J., Seifritz, E., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.008 · Cited by 66
Metaplastic Effects of Subanesthetic Ketamine on CA1 Hippocampal Function
Izumi, Y., & Zorumski, C. F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.002 · Cited by 63
Zorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
“Given the prevalence of MDD and TRMD, it is clear that TRMD is common, perhaps affecting as many as 3.5 million persons in the United States alone (1, 21).”
BackgroundInfluentialYang, C., Zhou, Z.-Q., Gao, Z.-Q., Shi, J.-Y., & Yang, J.-J. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.022 · Cited by 55
Differential regulation of GluA1 expression by ketamine and memantine
Zhang, K., Yamaki, V. N., Wei, Z., Zheng, Y., & Cai, X. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.09.002 · Cited by 51
Skosnik, P. D., Sloshower, J., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179800 · Cited by 51
“For example, converging lines of evidence from human neuroimaging, postmortem studies, and animal models have implicated altered synaptic connections and neuroplasticity in depression (Brown et al., 2004; Holmes et al., 2019; Machado-Vieira et al., 2009; Maes et al., 2009; Marazziti et al., 2010; Marsden, 2013; Sandi…”
BackgroundAction potential-independent and pharmacologically unique vesicular serotonin release from dendrites
Colgan, L. A., Cavolo, S. L., Commons, K. G., & Levitan, E. S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0020-12.2012 · Cited by 48
“In this light, it is striking that the NMDA receptor antagonist ketamine and the L-type Ca2 channel inhibitor nimodipine have antidepressant effects in humans (Machado-Vieira et al., 2009; Casamassima et al., 2010) and that Cav1.”
BackgroundAligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
Ketamine metabolite pilot study in a suicidal depression trial
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Parris, M. S., Burke, A. K., Suckow, R. F., Cooper, T. B., & Mann, J. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.08.005 · Cited by 41
Clinical specificity profile for novel rapid acting antidepressant drugs
Scala, M., Fanelli, G., De Ronchi, D., Serretti, A., & Fabbri, C. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000488 · Cited by 41
Stippl, A., Scheidegger, M., Aust, S., Herrera, A., Bajbouj, M., Gärtner, M., & Grimm, S. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.028 · Cited by 29
Yang, C., Li, W.-Y., Yu, H.-Y., Gao, Z.-Q., Liu, X.-L., Zhou, Z.-Q., & Yang, J.-J. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/175619 · Cited by 29
(2014) · Europe PMC (PubMed Central) · Cited by 25
Cai, M., Zhu, Y., Shanley, M. R., Morel, C., Ku, S. M., Zhang, H., Shen, Y., Friedman, A. K., & Han, M.-H. (2023) · Neurobiology of Stress · doi:10.1016/j.ynstr.2023.100565 · Cited by 18
Metadata
- Authors
- Machado-Vieira, R., Salvadore, G., DiazGranados, N., & Zarate, C. A.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 123
- Issue
- 2
- Pages
- 143-150
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2027572751
- Cited by
- 276
- References
- 97
- FWCI
- 16.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.